European Lithium has dispatched the scheme booklet for its proposed merger with NASDAQ-listed Critical Metals Corp., putting shareholders and optionholders on the path to votes on 22 October. The transaction remains conditional on securityholder, Court and regulatory approvals, with implementation targeted for 5 November.
- Scheme booklet and voting materials dispatched to EUR securityholders
- Shareholder and optionholder meetings scheduled for 22 October
- CRML share exchange ratio due on 21 October
- Independent Board Committee recommendation remains conditional
- Merger still requires votes, Court approval and other conditions
Scheme Booklet Puts EUR Holders on the Clock
European Lithium Limited (ASX:EUR, FRA:PF8, OTC:EULIF) has dispatched the scheme booklet for its proposed merger with NASDAQ-listed Critical Metals Corp. (NASDAQ:CRML), moving the transaction from regulatory preparation into the shareholder decision phase. CRML proposes to acquire all issued EUR shares and listed options through two Court-approved schemes of arrangement.
The materials include personalised proxy forms for the General Meeting and both scheme meetings, along with an opt-in form for eligible securityholders who want to receive net cash proceeds from the sale of the new CRML shares they would otherwise receive. The booklet also contains the Independent Expert’s Report, which is likely to be central to how holders assess the proposed exchange before voting.
Three Votes and a Floating Ratio
EUR securityholders will vote at a General Meeting at 10:00am AWST on 22 October, followed by the Share Scheme Meeting at 10:30am. The Option Scheme Meeting is scheduled for 11:00am or after the Share Scheme Meeting concludes. Related-party resolutions also form part of the approval process described in the timetable.
A key number will arrive one day before those meetings. The Share Scheme Transaction Ratio will be calculated using CRML’s volume-weighted average price through 20 October and announced at 9:00am AWST on 21 October. That timing means the ratio will be known after proxy lodgement deadlines but before the votes, leaving holders who have already lodged proxies able to revoke them or attend and vote in person instead.
Recommendation Comes With Express Qualifications
The Independent Board Committee continues to recommend that holders vote in favour of the relevant scheme, but only in the absence of a superior proposal and provided the Independent Expert continues to conclude that the scheme is in the best interests of the relevant securityholders. Michael Carter, the independent EUR director, intends to vote shares and options he holds or controls in favour on the same basis.
EUR specifically draws attention to personal benefits Mr Carter may receive if the schemes are implemented. That disclosure does not alter the committee’s stated recommendation, but it is a material qualification for holders weighing the board’s position against the expert’s report and the final exchange ratio.
Court Approval Still Stands Between Vote and Completion
Even if the required majorities approve the schemes, the proposed timetable still calls for a second Court hearing on 26 October. If the schemes become effective, EUR trading is expected to end on 27 October, the record date is set for 29 October, and consideration is targeted to be provided on 5 November. New CRML shares are scheduled to begin trading on NASDAQ on 6 November.
Those dates are indicative rather than guaranteed: the announcement says they remain subject to conditions precedent, Court and regulatory approvals, and possible changes approved by the relevant parties and authorities. The immediate test is therefore not completion, but whether holders are satisfied with the booklet, the expert’s conclusion and the ratio that emerges before the meetings.
Bottom Line?
The merger has reached its decisive shareholder phase, but the final exchange ratio and the conditions attached to the board recommendation leave important questions open before the 22 October votes.
Questions in the middle?
- Will the final CRML share exchange ratio materially change the appeal of the proposed consideration?
- How will EUR securityholders respond to the Independent Board Committee’s conditional recommendation and disclosed personal benefits?
- Can the transaction clear all shareholder, Court and regulatory conditions on the indicative timetable?